Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways.

Miner K, Labitzke K, Liu B, Wang P, Henckels K, Gaida K, Elliott R, Chen JJ, Liu L, Leith A, Trueblood E, Hensley K, Xia XZ, Homann O, Bennett B, Fiorino M, Whoriskey J, Yu G, Escobar S, Wong M, Born TL, Budelsky A, Comeau M, Smith D, Phillips J, Johnston JA, McGivern JG, Weikl K, Powers D, Kunzelmann K, Mohn D, Hochheimer A, Sullivan JK.

Front Pharmacol. 2019 Feb 14;10:51. doi: 10.3389/fphar.2019.00051. eCollection 2019.

2.

Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment.

Zhang M, Lee F, Knize A, Jacobsen F, Yu S, Ishida K, Miner K, Gaida K, Whoriskey J, Chen C, Gunasekaran K, Hsu H.

Clin Exp Rheumatol. 2019 Feb 15. [Epub ahead of print]

PMID:
30789152
3.

Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430).

Gonzalez-Lopez de Turiso F, Hao X, Shin Y, Bui M, Campuzano ID, Cardozo M, Dunn MC, Duquette J, Fisher B, Foti RS, Henne K, He X, Hu YL, Kelly RC, Johnson MG, Lucas BS, McCarter J, McGee LR, Medina JC, Metz D, San Miguel T, Mohn D, Tran T, Vissinga C, Wannberg S, Whittington DA, Whoriskey J, Yu G, Zalameda L, Zhang X, Cushing TD.

J Med Chem. 2016 Aug 11;59(15):7252-67. doi: 10.1021/acs.jmedchem.6b00827. Epub 2016 Jul 25.

PMID:
27411843
4.

Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors.

Shin Y, Suchomel J, Cardozo M, Duquette J, He X, Henne K, Hu YL, Kelly RC, McCarter J, McGee LR, Medina JC, Metz D, San Miguel T, Mohn D, Tran T, Vissinga C, Wong S, Wannberg S, Whittington DA, Whoriskey J, Yu G, Zalameda L, Zhang X, Cushing TD.

J Med Chem. 2016 Jan 14;59(1):431-47. doi: 10.1021/acs.jmedchem.5b01651. Epub 2015 Dec 21.

PMID:
26652588
5.

Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.

Cushing TD, Hao X, Shin Y, Andrews K, Brown M, Cardozo M, Chen Y, Duquette J, Fisher B, Gonzalez-Lopez de Turiso F, He X, Henne KR, Hu YL, Hungate R, Johnson MG, Kelly RC, Lucas B, McCarter JD, McGee LR, Medina JC, San Miguel T, Mohn D, Pattaropong V, Pettus LH, Reichelt A, Rzasa RM, Seganish J, Tasker AS, Wahl RC, Wannberg S, Whittington DA, Whoriskey J, Yu G, Zalameda L, Zhang D, Metz DP.

J Med Chem. 2015 Jan 8;58(1):480-511. doi: 10.1021/jm501624r. Epub 2014 Dec 3.

PMID:
25469863
6.

G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium.

Yang Y, Lu JY, Wu X, Summer S, Whoriskey J, Saris C, Reagan JD.

Pharmacology. 2010;86(1):1-5. doi: 10.1159/000314164. Epub 2010 Jun 19.

PMID:
20559017
7.

Spontaneous colitis occurrence in transgenic mice with altered B7-mediated costimulation.

Kim G, Turovskaya O, Levin M, Byrne FR, Whoriskey JS, McCabe JG, Kronenberg M.

J Immunol. 2008 Oct 15;181(8):5278-88.

8.

Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts.

Ara G, Baher A, Storm N, Horan T, Baikalov C, Brisan E, Camacho R, Moore A, Goldman H, Kohno T, Cattley RC, Van G, Gaida K, Zhang M, Whoriskey JS, Fong D, Yoshinaga SK.

Int J Cancer. 2003 Feb 10;103(4):501-7.

9.

ICOS is essential for effective T-helper-cell responses.

Tafuri A, Shahinian A, Bladt F, Yoshinaga SK, Jordana M, Wakeham A, Boucher LM, Bouchard D, Chan VS, Duncan G, Odermatt B, Ho A, Itie A, Horan T, Whoriskey JS, Pawson T, Penninger JM, Ohashi PS, Mak TW.

Nature. 2001 Jan 4;409(6816):105-9.

PMID:
11343123
10.

Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS.

Yoshinaga SK, Zhang M, Pistillo J, Horan T, Khare SD, Miner K, Sonnenberg M, Boone T, Brankow D, Dai T, Delaney J, Han H, Hui A, Kohno T, Manoukian R, Whoriskey JS, Coccia MA.

Int Immunol. 2000 Oct;12(10):1439-47.

PMID:
11007762
11.

T-cell co-stimulation through B7RP-1 and ICOS.

Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, Shih G, Zhang M, Coccia MA, Kohno T, Tafuri-Bladt A, Brankow D, Campbell P, Chang D, Chiu L, Dai T, Duncan G, Elliott GS, Hui A, McCabe SM, Scully S, Shahinian A, Shaklee CL, Van G, Mak TW, Senaldi G.

Nature. 1999 Dec 16;402(6763):827-32.

PMID:
10617205
12.

A Neu differentiation factor (NDF) domain essential for proliferation and alterations in morphology of colonic epithelial cells in vitro.

Whoriskey JS, Pekar SK, Elliott GS, Hara S, Liu N, Lenz DM, Zamborelli T, Mayer JP, Tarpley JE, Lacey DL, Ratzkin B, Yoshinaga SK.

Growth Factors. 1998;15(4):307-21.

PMID:
9714914
13.

Point mutations upstream of the yeast ADH2 poly(A) site significantly reduce the efficiency of 3'-end formation.

Hyman LE, Seiler SH, Whoriskey J, Moore CL.

Mol Cell Biol. 1991 Apr;11(4):2004-12.

14.
15.

SUBSTITUTES FOR TUBERCULIN AS A MEANS OF DIAGNOSIS.

Cabot RC, Whoriskey JJ.

J Boston Soc Med Sci. 1899 Jan 17;3(4):71-74. No abstract available.

Supplemental Content

Loading ...
Support Center